Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial-Reference-Cited by-同舟云学术

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

Published:2021-10 Issue:10 Volume:21 Page:1383-1394
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Chappell Keith J,Mordant Francesca L,Li Zheyi,Wijesundara Danushka K,Ellenberg Paula,Lackenby Julia A,Cheung Stacey T M,Modhiran Naphak,Avumegah Michael S,Henderson Christina L,Hoger Kym,Griffin Paul,Bennet Jillian,Hensen Luca,Zhang Wuji,Nguyen Thi H O,Marrero-Hernandez Sara,Selva Kevin J,Chung Amy W,Tran Mai H,Tapley Peter,Barnes James,Reading Patrick C,Nicholson Suellen,Corby Stavroula,Holgate Thomas,Wines Bruce D,Hogarth P Mark,Kedzierska Katherine,Purcell Damian F J,Ranasinghe Charani,Subbarao Kanta,Watterson Daniel,Young Paul R,Munro Trent P

Funder

National Health and Medical Research Council

Queensland Government

Coalition for Epidemic Preparedness Innovations

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference41 articles.

1. Accelerating a safe and effective COVID-19 vaccine,2020

2. Draft landscape and tracker of COVID-19 candidate vaccines,2021

3. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein;Walls;Cell,2020